TY - JOUR
T1 - Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications
T2 - A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group
AU - Shinohara, Akihito
AU - Oshima, Kumi
AU - Fuji, Shigeo
AU - Umeda, Katsutsugu
AU - Kako, Shinichi
AU - Kurokawa, Mineo
AU - Tsukada, Nobuhiro
AU - Kasai, Masanobu
AU - Kondo, Takakazu
AU - Hashii, Yoshiko
AU - Nakamae, Hirohisa
AU - Ikegame, Kazuhiro
AU - Kosaka, Yoshiyuki
AU - Shimada, Akira
AU - Nawa, Yuichiro
AU - Makoto, Yoshimitsu
AU - Yoshiko, Atsuta
AU - Fukuda, Takahiro
AU - Tanaka, Junji
AU - Ogata, Masao
N1 - Funding Information:
Financial disclosure: This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from Japan Agency for Medical Research and Development.
Funding Information:
The authors are grateful for the work of all the physicians and data managers at the centers who contributed valuable data on transplantation to the JSHCT. The authors would also like to thank all members of the Transplant Registry Unified Management committees at the JSHCT for their dedicated data management. Financial disclosure: This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from Japan Agency for Medical Research and Development. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: A. Shino designed the study, analyzed data, and wrote the manuscript. K.O. and S.F. advised on methods and revised the manuscript. K.U. S.K. M.K. N.T. M.K. T.K. Y.H. H.N. K.I. Y.K. A. Shima, Y.N. and Y.M. collected data and revised the manuscript. T.F. and J.T. collected data, revised the manuscript, and were responsible for data management at the JSHCT. Y.A. managed the unified registry database and revised the manuscript. O.M. advised on the methods, revised the manuscript, and was responsible for the working group. A. Shino, K.O. S.F. Y.N. T.F. and O.M. are the members of the working group. Financial disclosure: See Acknowledgments on page 74
Publisher Copyright:
© 2019 American Society for Transplantation and Cellular Therapy
PY - 2020/1
Y1 - 2020/1
N2 - Little is known about stem cell transplantation in solid organ transplantation (SOT) recipients. We conducted a nationwide retrospective survey of Japan Society for Hematopoietic Stem Cell Transplantation centers. A total of 19 patients who underwent 22 hematopoietic stem cell transplantations (HSCTs) after SOT were identified: 5 autologous HSCTs and 17 allogeneic HSCTs were performed. Patients who underwent autologous HSCT received a liver (n = 4) or kidney (n = 1) transplant. All 5 patients achieved neutrophil engraftment, and 2 of 3 patients with hepatoblastoma were alive at 1 year after HSCT. Allogeneic HSCT was performed in 16 patients (7 liver transplant recipients and 9 kidney transplant recipients). Among these, 2 donors were identical for both transplantations. All but 1 patient achieved neutrophil engraftment. The 5-year overall survival rate was 41.7%, but that in patients with malignant disease (n = 13) was much lower than the overall rate (23.1%). Only 1 patient with malignant disease underwent allogeneic HSCT in nonremission. In allogeneic HSCT after kidney transplantation, post-transplantation (1 year) kidney function in 5 evaluable patients was significantly lower than that before allogeneic HSCT, and 3 patients experienced renal rejection. However, no severe hepatic rejection was noted. In SOT recipients, HSCT is a potentially curable treatment for hematologic disorders, but it must be performed with caution, especially in patients with malignancy.
AB - Little is known about stem cell transplantation in solid organ transplantation (SOT) recipients. We conducted a nationwide retrospective survey of Japan Society for Hematopoietic Stem Cell Transplantation centers. A total of 19 patients who underwent 22 hematopoietic stem cell transplantations (HSCTs) after SOT were identified: 5 autologous HSCTs and 17 allogeneic HSCTs were performed. Patients who underwent autologous HSCT received a liver (n = 4) or kidney (n = 1) transplant. All 5 patients achieved neutrophil engraftment, and 2 of 3 patients with hepatoblastoma were alive at 1 year after HSCT. Allogeneic HSCT was performed in 16 patients (7 liver transplant recipients and 9 kidney transplant recipients). Among these, 2 donors were identical for both transplantations. All but 1 patient achieved neutrophil engraftment. The 5-year overall survival rate was 41.7%, but that in patients with malignant disease (n = 13) was much lower than the overall rate (23.1%). Only 1 patient with malignant disease underwent allogeneic HSCT in nonremission. In allogeneic HSCT after kidney transplantation, post-transplantation (1 year) kidney function in 5 evaluable patients was significantly lower than that before allogeneic HSCT, and 3 patients experienced renal rejection. However, no severe hepatic rejection was noted. In SOT recipients, HSCT is a potentially curable treatment for hematologic disorders, but it must be performed with caution, especially in patients with malignancy.
KW - Hematopoietic stem cell transplantation
KW - Liver failure
KW - Renal failure
KW - Solid organ transplantation
KW - Transplantation-related complications
UR - http://www.scopus.com/inward/record.url?scp=85073074361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073074361&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2019.08.021
DO - 10.1016/j.bbmt.2019.08.021
M3 - Article
C2 - 31494230
AN - SCOPUS:85073074361
SN - 1083-8791
VL - 26
SP - 66
EP - 75
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 1
ER -